Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 96 clinical trials
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

previously treated with ruxolitinib. The primary objective of the study is to evaluate the percentage of subjects with at least 35% spleen volume reduction in the fedratinib and the BAT arms.

polycythemia
essential thrombocythemia
cancer
anemia
ruxolitinib
  • 103 views
  • 27 Sep, 2021
  • 125 locations
To Assess the Safety Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.

myelofibrosis
ruxolitinib
  • 0 views
  • 08 Aug, 2021
  • 12 locations
Activity Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant

This open-label, single-arm, Phase II multi-center study will enroll approximately 42 subjects and investigate the activity, pharmacokinetics and safety of ruxolitinib added to the subject's

immunosuppressive agents
corticosteroids
cancer
ruxolitinib
chronic graft versus host disease
  • 3 views
  • 26 Jul, 2021
  • 31 locations
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

children with acute lymphoblastic leukemia (ALL) and acute lymphoblastic lymphoma (LLy). To determine the tolerability of combination therapy with ruxolitinib and Early Intensification therapy in

pegaspargase
vincristine
lymphoblastic lymphoma
idarubicin
mercaptopurine
  • 231 views
  • 02 Sep, 2021
  • 7 locations
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

This is a Phase 2, multicenter, open-label study to evaluate the efficacy and safety of luspatercept in subjects with MPN-associated myelofibrosis and anemia with and without RBC-transfusion dependence. The study is divided into a Screening Period, a Treatment Period (consisting of a Primary Phase, a Day 169 Disease Response Assessment, …

polycythemia
cancer
vasectomy
anemia
erythropoietin
  • 395 views
  • 25 Aug, 2021
  • 26 locations
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/L). Approximately 348 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 232 patients) or …

neutrophil count
blast cells
essential thrombocythemia
thrombocytosis
renal function
  • 506 views
  • 21 Aug, 2021
  • 178 locations
Ruxolitinib for Premalignant Breast Disease

This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive

atypical ductal hyperplasia
neutrophil count
carcinoma in situ
lobular carcinoma in situ
breast disease
  • 16 views
  • 18 Feb, 2021
  • 7 locations
Ruxolitinib in Operable Head and Neck Cancer

The purpose of this study is to assess the safety and efficacy of ruxolitinib in patients with operable Head and neck squamous cell carcinoma (HNSCC) who are planned for definitive surgery.

neutrophil count
cancer
serum pregnancy test
squamous cell carcinoma
neck cancer
  • 4 views
  • 16 Aug, 2021
  • 2 locations
Low Dose Ruxolitinib in Combination With Methylprednisolone

This study is to determine the efficacy and safety of combined Low dose Ruxolitinib With Methylprednisone as Initial Therapy for the aGVHD(acute graft-versus-host disease )

regenerating islet derived protein 3
corticosteroids
acute graft-versus-host disease
ruxolitinib 5 mg
cancer
  • 0 views
  • 25 Jan, 2021
  • 1 location
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

this study is: Ruxolitinib

blast cells
leukemia
hla-a
filgrastim
absolute neutrophil count
  • 36 views
  • 25 Jan, 2021
  • 6 locations